BlueCross BlueShield of Tennessee Medical Policy Manual

Sublingual Liquid Immunotherapy

DESCRIPTION

Sublingual liquid immunotherapy is a proposed treatment for allergies administered in liquid or drops placed under the tongue, usually given on a daily basis. Currently there is no immunotherapy antigen in liquid form cleared for sublingual use by the FDA.

Allergic rhinitis (AR) is a global health problem. Symptomatic treatment is available, but some individuals do not tolerate or respond well to these treatments. Only allergen immunotherapy offers persistent, long-term benefits. In clinical practice, subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) tablets are the most common methods used.

For sublingual tablet immunotherapy, please refer to MCG Care Guideline - Immunotherapy, Sublingual

POLICY

IMPORTANT REMINDERS

ADDITIONAL INFORMATION

Many questions currently remain unanswered regarding sublingual liquid immunotherapy, such as effective dosing, optimal starting time and schedule, and duration of therapy

SOURCES

American Academy of Allergy, Asthma & Immunology (AAAAI) and American College of Allergy, Asthma & Immunology (ACAAI). (2017). Sublingual immunotherapy - a focused allergen immunotherapy practice parameter update. Retrieved May 4, 2017 from http://www.aaaai.org.

Blue Cross Blue Shield Association. Evidence Positioning System. (10:2018). Sublingual immunotherapy as a technique of allergen-specific therapy (2.01.17) Retrieved March 15, 2019 from https://www.evidencepositioningsytem. (39 articles and/or guidelines reviewed)

Centers for Medicare & Medicaid Services. CMS.gov. National Coverage Determination (NCD) for Antigens prepared for sublingual administration (110.9). Retrieved June 25, 2015 from http://www.cms.gov.

Creticos, P., Esch, R., Couroux, P., Gentile, D., D’Angelo, P., Whitlow, B, et al. (2013). Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. The Journal of Allergy and Clinical Immunology, 133 (3), 751-758. (Level 2 evidence)

Elenburg, A., & Blaiss, M. (2014). Current status of sublingual immunotherapy in the United States. World Allergy Organization Journal, 7 (1), 24. (Level 5 evidence)

Pfaar, O., Bachert, C, Kuna, P., Panzner, P., Džupinová, M., Klimek, L., et al. (2019). Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. Journal of Allergy and Clinical Immunology, 143 (3), 970-977. Abstract retrieved March 15, 2019 from PubMed database.

ORIGINAL EFFECTIVE DATE:  11/14/2015

MOST RECENT REVIEW DATE:  4/11/2019

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.